Bristol Myers Squibb Co. devoted half a page of its annual report to its diversity, equity and inclusion efforts, going so ...

Jim Cramer, the host of Mad Money, recently pointed out a significant gap in the American education system, emphasizing that ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer handbags, luxury face creams and trips to Paris have all fallen victim to ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...